Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
Diagnosis
...orectal carcinoma patients being c...
...RAF p.V600 (BRAF c. 1799 (p.V600) mutational anal...
...tional analysis should be performed...
...nicians should order mismatch repair st...
...re is insufficient evidence to recommend BRA...
...insufficient evidence to recommend P...
...is insufficient evidence to recommend...
...tic or recurrent colorectal carcinoma...
...fixed paraffin embedded tissue is an...
...aboratories must use validated color...
...e of molecular biomarker testing for colorecta...
...s must validate the performance of IHC testin...
...es must provide clinically appropriate turnarou...
...and IHC biomarker testing in colorectal...
...ries should establish policies to ensure eff...
...he patient’s medical team, including patholog...
...s that require send out of tests f...
...ogists must evaluate candidate spec...
...ould use colorectal carcinoma molecular b...
...ctal carcinoma molecular biomarker results...
...rcinoma molecular biomarker testing report...
...ories must incorporate colorectal carci...
Table 1. Outcomes of RAS Mutations...
...ordance Rates Between Primary and Metastat...